AzTrials
AzTrials

Penile Squamous Cell CarcinomaPhase 2APOLONCT07808359

Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell Carcinoma

A Phase 2 study testing Amivantamab in people with Penile Squamous Cell Carcinoma and Metastatic Penile Squamous Cell Carcinoma, run by Latin American Cooperative Oncology Group at 1 site in Brazil.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This is a collaborative, multicenter, open-label, Phase 2 clinical trial (APOLO TRIAL / LACOG 2425) designed to evaluate the efficacy, safety, and tolerability of subcutaneous amivantamab monotherapy in adult patients with histologically confirmed recurrent or metastatic penile squamous cell carcinoma (PSCC). Read more about this study

Who is it for?
Ages 18 to 85 years, men only
What is being tested?
Amivantamab
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
58 participants
Where
1 siteBrazil
Study dates
Nov 2026to Nov 2029
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • Men only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Histologically confirmed diagnosis of penile squamous cell carcinoma.
  • Metastatic or locally advanced disease not amenable to therapy of curative intent (e.g., surgery, radiotherapy, chemoradiotherapy) in the opinion of the investigator.
  • Measurable disease per RECIST v1.1 as assessed by the local site investigator/radiologist. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  • Have received up to 2 lines of previous systemic therapy. Documented disease progression on or after first-line or second-line platinum-based chemotherapy for locally advanced/metastatic disease. Disease progression within 12 months of (neo) adjuvant chemotherapy completion is considered first-line of therapy. Previous anti-PD-1/anti-PD-L1 therapy is allowed.
  • Participants must have tumor tissue available for HPV testing. HPV status will be determined by IHC for p16 or FISH (both are acceptable) assessed by the local laboratory or central laboratory. Note: A copy of the local test report documenting the HPV status must be included in the participant records and must also be submitted to the sponsor.
  • Male participant aged at least 18 years and no more than 85 years at the time of signing the informed consent form.
Show all 18Show fewer
  • Male Participants (Reproductive Potential). If capable of producing sperm, the participant agrees to the following from the first dose of study intervention and for at least 120 days after the last dose:
  • Refrain from donating sperm.
  • Use a penile/external condom when engaging in penile-vaginal intercourse with a partner of childbearing potential who is not currently pregnant, PLUS the partner must use an additional highly effective contraceptive method. Note: A condom alone is not considered highly effective, as breakage or leakage may occur. If the participant is azoospermic (vasectomized or due to medical cause, documented by medical records, examination, or history), no contraception is required. Contraceptive use must be consistent with local regulations for participants in clinical studies. If local label requirements for amivantamab are more stringent, those must be followed.
  • The participant (or legally acceptable representative, if applicable) provides written informed consent for the study.
  • Life expectancy of at least 12 weeks in the opinion of the investigator.
  • Willing and able to provide an archival tumor tissue sample or newly obtained core/incisional/excisional biopsy of a tumor lesion not previously irradiated. Formalin-fixed, paraffin-embedded (FFPE) tissue blocks are preferred; newly obtained biopsies are preferred to archived tissue (minimum 10-15 unstained slides recommended).
  • Adverse events due to previous anticancer therapies must have recovered to ≤ Grade 1 or baseline (except for alopecia and vitiligo). Participants with endocrine-related AEs adequately managed on stable hormone replacement therapy are eligible.
  • Adequate organ function defined by the laboratory values in Table 2 (specimens collected within 14 days prior to the start of study intervention). This population definition ensures a homogeneous group of platinum-refractory patients with measurable disease while maintaining broad applicability across age, race, and ethnicity, in line with the orphan nature of the disease and the universal EGFR overexpression observed in penile squamous cell carcinoma.
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Evaluation is to be performed within 7 days prior to the start of study intervention.
  • Be willing and able to adhere to the study visit schedule and other protocol requirements, including the completion of all scheduled study procedures, laboratory tests, tumor assessments, and patient-reported outcome questionnaires.
  • Participants with chronic hepatitis B virus (HBV) infection (HBsAg positive) are eligible if they have received HBV antiviral therapy for at least 4 weeks and have an undetectable HBV viral load prior to the start of study intervention. Participants should remain on antiviral therapy throughout study intervention and follow local guidelines for HBV antiviral therapy after completion of study intervention. Note: Hepatitis B serology testing at screening is not required unless if there is a known history of HBV infection.
  • Participants with a history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening and they have completed curative antiviral therapy at least 4 weeks prior to the start of study intervention. Note: Hepatitis C serology/viral load testing at screening is not required unless if there is a known history of HCV infection.

Who cannot join

  • History of interstitial lung disease (ILD)/pneumonitis/pulmonary fibrosis that required systemic steroids, or current ILD/pneumonitis (including radiation pneumonitis).
  • Any evidence of active or suspected ILD/pneumonitis/pulmonary fibrosis on screening chest imaging (CT preferred).
  • Participant with untreated brain metastases Note: Participants with definitively, locally treated metastases that are clinically stable and asymptomatic for at least 8 weeks and who are off or receiving low-dose corticosteroid treatment (≤10 mg prednisone or equivalent) for at least 4 weeks prior to the first dose of study treatment are eligible.
  • Participant has a medical history or known presence of leptomeningeal disease, or participant has spinal cord compression not definitively treated with surgery or radiation.
  • Uncontrolled illness, including but not limited to (applicable to all participants):
  • Diabetes.
Show all 39Show fewer
  • Ongoing or active infection (includes infection requiring treatment with antimicrobial therapy [participants will be required to complete antibiotics 1 week prior to starting study treatment]) or diagnosed or suspected viral infection.
  • Active bleeding diathesis.
  • Impaired oxygenation requiring continuous oxygen supplementation.
  • Known allergies, hypersensitivity, or intolerance to excipients of amivantamab or rHuPH20 (refer to the IB).
  • Participant has a history of clinically significant cardiovascular disease including, but not limited to the following:
  • Diagnosis of deep vein thrombosis or pulmonary embolism within 8 weeks prior to the first dose of study treatment or any of the following within 6 months prior to the first dose of study treatment: myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary/peripheral artery bypass graft, or any acute coronary syndrome. Clinically non-significant thrombosis, such as non-obstructive catheter-associated clots, are not exclusionary.
  • Prolonged QTcF interval >480 msec or clinically significant cardiac arrhythmia or electrophysiologic disease (eg, placement of implantable cardioverter defibrillator or atrial fibrillation with uncontrolled rate). Note: Participants with cardiac pacemakers who are clinically stable are eligible.
  • Uncontrolled (persistent) hypertension: systolic blood pressure >180 mm Hg; diastolic blood pressure >100 mm Hg.
  • Congestive heart failure defined as NYHA Class III, IV or Hospitalization for congestive heart failure (any NYHA Class) within 6 months of the first dose of study treatment.
  • Pericarditis/clinically significant pericardial effusion.
  • Myocarditis.
  • Clinically significant arrhythmias requiring medication
  • Participant has, or will have, any of the following:
  • An invasive operative procedure with entry into a body cavity, within 4 weeks or without complete recovery before the first administration of study treatment. Thoracentesis, if needed, and percutaneous biopsy for baseline tumor tissue sample may be done less than 4 weeks prior to the first administration of study treatment, as long as the participant has adequately recovered from the procedure prior to the first dose of study treatment in the clinical judgement of the investigator.
  • Significant traumatic injury within 3 weeks before the start of the first administration of study treatment (all wounds must be fully healed prior to Day1).
  • Expected major surgery while the investigation agent is being administered or within 6 months after the last dose of study treatment.
  • HIV-positive participants are not eligible if they meet any of the following:
  • Detectable viral load (ie, >50 copies/mL) at screening.
  • CD4+ count <300 cells/mm3 at screening.
  • AIDS-defining opportunistic infection within 6 months of screening.
  • Not receiving HAART. Any changes in HAART due to resistance/progression should occur at least 3 months prior to screening. A change in HAART due to toxicity is allowed up to 4 weeks prior to screening. Note: HAART that could interfere with study treatment is excluded (consult the sponsor for a review of medications prior to enrollment).
  • Active hepatitis of infectious origin.
  • Seropositive for hepatitis B: defined by a positive test for HBsAg. Participants with resolved infection (ie, participants who are HBsAg negative with anti-HBc with or without the presence of anti-HBs) must be screened using RT-PCR measurement of HBV DNA levels. Those who are RT-PCR positive will be excluded. Participants with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by RT-PCR.
  • Positive hepatitis C antibody test result at screening or within 3 months prior to the first dose of study treatment. Note: Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled only if a confirmatory negative HCV RNA test is obtained.
  • Positive hepatitis C RNA test result at screening or within 3 months prior to the first dose of study treatment. Note: Test is optional and participants with negative hepatitis C antibody test are not required to also undergo hepatitis C RNA testing.
  • Other clinically active liver diseases of infectious origin.
  • Prior treatment with any EGFR×MET bispecific antibody.
  • Severe or uncontrolled ocular disorders including severe dry eye syndrome, severe Meibomian gland dysfunction, severe blepharitis, or corneal disease that may preclude safe administration of amivantamab (e.g., history of corneal ulceration, persistent epithelial defect).
  • Prior systemic anticancer therapy (including investigational agents) within 14 days or 4 half-lives (whichever is longer) prior to first dose. The maximum required washout is 28 days.
  • Prior radiotherapy within 14 days prior to first dose or unresolved radiation-related toxicity requiring corticosteroids. Note: Limited palliative radiotherapy (≤10 fractions) to non-target lesions is allowed if completed ≥7 days before first dose.
  • Requires prohibited medication that cannot be discontinued, substituted, or temporarily interrupted during the study; see Section 6.6 Concomitant Therapy for prohibited therapies.
  • Received an investigational treatment (including investigational vaccines, but not including anticancer therapy) or used an invasive investigational medical device within 6 weeks before the planned first dose of study treatment.
  • Any medical, psychiatric, social or other condition that, in the opinion of the investigator, would preclude safe participation or compliance with study procedures.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Project Manager contact

+55 (51) 3384.5334

lacog2425@lacog.group

Head of Operations contact

+55 (51) 3384.5334

laura.voelcker@lacog.group

Brazil1 site

  • Futtura Oncologia - Hub de Pesquisa Clínica

    Porto Alegre, Rio Grande do Sul, Rio Grande do Sul

    Rachel Molina, +55 51 99657-7731, rachel.molina@futturaoncologia.com

    Luísa Rabeno Fasolo

Other trials in Brazil

About this study

Official title: Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell Carcinoma Who Progressed to First-line Platinum-Based Chemotherapy: APOLO TRIAL (LACOG 2425)

This is a collaborative, multicenter, open-label, Phase 2 clinical trial (APOLO TRIAL / LACOG 2425) designed to evaluate the efficacy, safety, and tolerability of subcutaneous amivantamab monotherapy in adult patients with histologically confirmed recurrent or metastatic penile squamous cell carcinoma (PSCC). Eligible participants must have experienced disease progression on or after receiving at least one platinum-based chemotherapy regimen (with or without immunotherapy). The study allocates participants into two parallel non-randomized cohorts based on their human papillomavirus (HPV) status (HPV-positive and HPV-negative).

Read the detailed description

Penile squamous cell carcinoma (PSCC) is a rare and aggressive disease with near-universal EGFR protein overexpression and frequent MET activation, representing a significant unmet medical need following the failure of first-line platinum-based chemotherapy. Amivantamab is a fully human bispecific antibody targeting both EGFR and MET.

Study Design and Administration:

Participants receive subcutaneous amivantamab monotherapy across 21-day cycles. Dosing is weight-based (1,600 mg for less than 80 kg; 2,240 mg for 80 kg or greater on Cycle 1 Day 1, followed by 2,400 mg or 3,360 mg on Days 8 and 15 of Cycle 1, and every 3 weeks starting from Cycle 2 onwards). Treatment continues during the core treatment phase for up to 24 weeks or until disease progression, unacceptable toxicity, or consent withdrawal. Patients without progression at 24 weeks may enter an extension phase.

Primary Endpoint:

Objective Response Rate (ORR) assessed by the investigator per RECIST v1.1.

Secondary Endpoints:

Independent Central Review ORR (ORR-ICR), Disease Control Rate (DCR), Duration of Response (DoR), Progression-Free Survival (PFS), Overall Survival (OS), safety and tolerability (NCI-CTCAE v6.0), treatment compliance, post-progression therapies, and Patient-Reported Outcomes (EORTC QLQ-C30).

Exploratory Biomarker Research:

Evaluation of baseline tissue/blood biomarkers (HPV status, EGFR/MET expression), longitudinal tracking of ctDNA and HPV copy numbers, and exploration of acquired resistance mechanisms.

Sample Size and Design:

Using Simon's two-stage design, each cohort aims to enroll 27 evaluable patients (up to 29 patients per cohort to account for non-evaluable participants, totaling up to 58 patients overall). Each cohort includes a Stage 1 futility analysis after enrolling 13 patients.

Being tested
Amivantamab

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AmivantamabDrug

    Also called JNJ-61186372

    Subcutaneous injection of amivantamab monotherapy administered in 21-day cycles:

    • Cycle 1 Day 1: 1,600 mg (2,240 mg if body weight is 80 kg or greater)
    • Cycle 1 Days 8 and 15: 2,400 mg (3,360 mg if body weight is 80 kg or greater) once weekly
    • Cycle 2 and beyond (Day 1): 2,400 mg (3,360 mg if body weight is 80 kg or greater) every 3 weeks (Q3W) Treatment continues up to 24 weeks, or until disease progression, unacceptable toxicity, or consent withdrawal.
Study groups in NCT07808359
Study groupRoleWhat they receive
HPV Positive CohortExperimentalMale patients 18 years of age or older with histologically confirmed recurrent or metastatic penile squamous cell carcinoma (PSCC) who progressed on or after first-line platinum-based chemotherapy and have HPV-positive tumor status (determined by IHC for p16 or FISH).
Receives: Drug: Amivantamab
HPV Negative cohortExperimentalMale patients 18 years of age or older with histologically confirmed recurrent or metastatic penile squamous cell carcinoma (PSCC) who progressed on or after first-line platinum-based chemotherapy and have HPV-negative tumor status (determined by IHC for p16 or FISH).
Receives: Drug: Amivantamab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Objective Response Rate (ORR) by Investigator Assessment

    Percentage of participants who achieve a Best Overall Response of Partial Response (PR) or Complete Response (CR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

    Measured: Up to 24 weeks

Secondary outcomes (7)

  1. Objective Response Rate by Independent Central Review (ORR-ICR)

    Percentage of participants who achieve a confirmed PR or CR as assessed by Independent Central Review per RECIST v1.1.

    Measured: Up to 24 weeks

  2. Disease Control Rate (DCR)

    Percentage of participants achieving Complete Response (CR), Partial Response (PR), or Stable Disease (SD) as assessed by investigator per RECIST v1.1.

    Measured: Up to 24 weeks

  3. Duration of Response (DoR)

    Time from the first documented evidence of PR or CR to the date of first documented disease progression (per RECIST v1.1) or death due to any cause.

    Measured: Up to 12 months

  4. Progression-Free Survival (PFS)

    ime from the date of enrollment to the date of first documented disease progression (radiographically per RECIST v1.1 or clinically) or death due to any cause, whichever occurs first.

    Measured: Up to 12 months

  5. Overall Survival (OS)

    Time from the date of enrollment to the date of death due to any cause.

    Measured: Up to 12 months

  6. Incidence and Severity of Adverse Events (Safety and Tolerability)

    Incidence, nature, and severity of treatment-emergent adverse events (TEAEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 6.0.

    Measured: From baseline up to 30 days after the last dose of study treatment

  7. Patient-Reported Outcomes (PRO) - EORTC QLQ-C30

    Change from baseline in Quality of Life (QoL) scores assessed via the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Scores range from 0 to 100.

    Measured: Baseline and every 3 weeks up to 24 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Sep 2026
  2. Study startNov 2026 (estimated)
  3. Primary completionFeb 2029 (estimated)
  4. Study completionNov 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
Multicenter, open-label, non-randomized phase II study with two parallel cohorts stratified by human papillomavirus (HPV) status: HPV-positive cohort and HPV-negative cohort. Each cohort will be recruited and analyzed independently using Simon's two-stage design
Masking
None (open label)
Enrolment
58 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07808359
Sponsor's protocol ID
LACOG 2425
Acronym
APOLO
Status last verified
Sep 2026
First submitted
2 Sep 2026
Last updated
14 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Amivantamab in people with Penile Squamous Cell Carcinoma and Metastatic Penile Squamous Cell Carcinoma, run by Latin American Cooperative Oncology Group at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 18 inclusion and 39 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 14 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Project Manager (+55 (51) 3384.5334, lacog2425@lacog.group), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Objective Response Rate (ORR) by Investigator Assessment (time frame: Up to 24 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07808359.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in